Key terms

About APRE

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest APRE news

Apr 12 11:35am ET Aprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy Rating by TipRanks Apr 03 4:09pm ET Aprea Therapeutics files to sell 4.39M shares of common stock for holders by TipRanks Mar 27 4:05pm ET Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating by TipRanks Mar 27 8:08am ET Aprea Therapeutics price target raised to $11 from $9 at Wedbush by TipRanks Mar 26 11:15am ET Buy Rating Affirmed: Aprea Therapeutics Poised for Growth with Strong Pipeline Momentum into 2024 by TipRanks Mar 19 3:05pm ET Aprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug Pipeline by TipRanks Mar 14 11:01am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 13 11:07am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 12 4:43pm ET Aprea Therapeutics Secures Funding and Advances Drug Pipeline by TipRanks Mar 11 8:40am ET Aprea Therapeutics enters private placement financing for up to $34M by TipRanks Mar 11 8:30am ET Aprea Therapeutics announces FDA clearance of IND for APR-1051 by TipRanks Feb 07 5:10am ET Aprea Therapeutics Updates Corporate Presentation Materials by TipRanks Feb 06 8:23am ET Aprea Therapeutics announces IND application for APR-1051 by TipRanks Jan 27 4:03am ET Aprea Therapeutics Signs Sales Agreement with HCW by TipRanks Jan 26 6:06am ET Aprea Therapeutics files $150M mixed securities shelf by TipRanks

No recent press releases are available for APRE

APRE Financials

1-year income & revenue

Key terms

APRE Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

APRE Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Meta headquarters pictured on February 02, 2023 in Menlo Park, California.
Justin Sullivan/Getty Images
Meta’s stock plunges on ‘aggressive’ AI spending plans
The logo of Swiss bank UBS is seen at the company's headquarters in Zurich, Switzerland February 10, 2015. REUTERS/Arnd Wiegmann/File Photo
Arnd Wiegmann/Reuters
Switzerland says UBS may need more cash. The bank is fuming
Jamie Dimon, Chairman and Chief Executive officer (CEO) of JPMorgan Chase & Co. (JPM) speaks to the Economic Club of New York in Manhattan in New York City, U.S., April 23, 2024. REUTERS/Mike Segar
Mike Segar/Reuters
Jamie Dimon fears for the future of the free world and US debt
A bubble tea store operated by Sichuan Baicha Baidao in Shanghai, China, on April 23, 2024.
Raul Ariano/Bloomberg/Getty Images
Is the tea bubble bursting? ChaPanda shares plunge in Hong Kong IPO